Vertex Pharmaceuticals (VRTX) Liabilities and Shareholders Equity (2009 - 2026)

Vertex Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $26.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 15.75% year-over-year to $26.5 billion; the TTM figure through Mar 2026 stood at $101.0 billion (up 15.08% YoY), while the FY2025 annual figure was $25.6 billion, up 13.8% from the prior year.
• Liabilities and Shareholders Equity was $26.5 billion for Q1 2026 at Vertex Pharmaceuticals, up from $25.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $26.5 billion in Q1 2026 to a low of $14.3 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $21.2 billion across 5 years, with a median of $22.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity surged 35.13% in 2022, then retreated 4.34% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $18.2 billion in 2022, then climbed by 25.23% to $22.7 billion in 2023, then slipped by 0.87% to $22.5 billion in 2024, then advanced by 13.8% to $25.6 billion in 2025, then grew by 3.28% to $26.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $26.5 billion (Q1 2026), $25.6 billion (Q4 2025), and $24.9 billion (Q3 2025), per Business Quant data.